The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. WARNING: Important safety information is provided in a boxed warning ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Phase I data ...

Rituximab and lenalidomide combination therapy shows promise for relapsed/refractory indolent non-Hodgkin lymphoma, with high response and remission rates. The AUGMENT trial demonstrated favorable ...

CHICAGO — Lenalidomide (Revlimid) is a vital component of early therapy and maintenance for patients with multiple myeloma, but patients in first relapse who have disease that is refractory to ...

Assessing out-of-pocket cost differences in treatment for Medicare-eligible patients with favorable prognosis early-stage Hodgkin lymphoma. Economic burden and healthcare resource utilization (HRU) ...

The recommended starting dosage of lenalidomide for the treatment of MM is 25 mg/day p.o. on days 1-21 of a 28-day cycle. On the basis of the trials previously presented, the recommended dosage of ...

Lenalidomide is a cornerstone therapy for multiple myeloma (MM) and other hematologic malignancies, but conventional oral dosing is limited by high peak plasma concentrations, rapid clearance, and ...

waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma ...

The study tests two interventions: Elranatamab, a BCMA-CD3 bispecific antibody administered via injection, and Lenalidomide, an oral immunomodulatory drug. The goal is to determine which treatment ...

Genmab A/S (Nasdaq: GMAB) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell ...